## **Core Concept**
The question tests knowledge of antiglaucoma medications, specifically their safety profiles in pediatric patients. Antiglaucoma medications are used to reduce intraocular pressure (IOP) in conditions like glaucoma. The safety of these medications in infants is crucial due to potential systemic and ocular side effects.

## **Why the Correct Answer is Right**
The correct answer, , refers to **Prostaglandin analogs**, specifically **Latanoprost**. Prostaglandin analogs are generally contraindicated in pediatric patients, especially infants, due to potential risks of ocular and systemic side effects. They can cause changes in iris pigmentation and eyelash growth, and their safety profile in children has not been well established.

## **Why Each Wrong Option is Incorrect**
- **Option A:** - This option is incorrect because is not specified, but if we consider common antiglaucoma medications like (Beta-blockers), they can be used in children with careful monitoring.
- **Option B:** - This option is incorrect because (Carbonic anhydrase inhibitors) can be used in infants, though with caution and monitoring for systemic side effects.
- **Option D:** - This option is incorrect because (Alpha agonists) can also be used, though they might have more side effects; their use isn't as strictly contraindicated as prostaglandin analogs in infants.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that **Prostaglandin analogs**, such as **Latanoprost**, are generally avoided in infants due to their potential side effects. For pediatric glaucoma, other classes of medications like beta-blockers, alpha agonists, and carbonic anhydrase inhibitors are often considered first, keeping in mind the need for close monitoring.

## **Correct Answer:** .